Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1016/J.NANO.2020.102207 | ||||
| Año | 2020 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Carboplatin, administered as a single drug or in combination with paclitaxel, is the standard chemotherapy treatment for patients with ovarian cancer (OVCA). Recent evidence suggests that miRNAs associated with small extracellular vesicles (sEVs) participate in the development of chemoresistance. We studied the effect of carboplatin in a heterogeneity population of OVCA cells and their derived sEVs to identify mechanisms associated with chemoresistance. sEVs were quantified using an engineered superparamagnetic material, gold-loaded ferric oxide nanotubes and a screen-printed electrode. miR-21-3p, miR-21-5p, and miR-891-5p are enriched in sEVs, and they contribute to carboplatin resistance in OVCA. Using a quantitative MS/MS, miR-21-5p activates glycolysis and increases the expression of ATP-binding cassette family and a detoxification enzyme. miR-21-3p and miR-891-5p increase the expression of proteins involved in DNA repair mechanisms. Interestingly, the levels of miR-8915p within sEVs are significantly higher in patients at risk of ovarian cancer relapse. Identification of miRNAs in sEVs also provides the opportunity to track them in biological fluids to potentially determine patient response to chemotherapy. (C) 2020 Elsevier Inc. All rights reserved.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Alharbi, Mona | Mujer |
UNIV QUEENSLAND - Australia
UQ Centre for Clinical Research - Australia The University of Queensland - Australia |
| 2 | Sharma, Shayna | Mujer |
UNIV QUEENSLAND - Australia
UQ Centre for Clinical Research - Australia The University of Queensland - Australia |
| 3 | Guanzon, Dominic | Hombre |
UNIV QUEENSLAND - Australia
UQ Centre for Clinical Research - Australia The University of Queensland - Australia |
| 4 | Lai, Andrew | Hombre |
UNIV QUEENSLAND - Australia
UQ Centre for Clinical Research - Australia The University of Queensland - Australia |
| 5 | ZUNIGA-ARBALTI, FELIPE ANDRES | Hombre |
Universidad de Concepción - Chile
|
| 6 | Shiddiky, Muhammad J. A. | Hombre |
Griffith Univ - Australia
Griffith University - Australia |
| 7 | Yamauchi, Y. | Hombre |
UNIV QUEENSLAND - Australia
The University of Queensland - Australia |
| 8 | SALAS-BURGOS, ALEXIS MARCELO | Hombre |
Universidad de Concepción - Chile
|
| 9 | He, Yaowu | - |
UNIV QUEENSLAND - Australia
The University of Queensland - Australia |
| 10 | Pejovic, Tanja | Mujer |
OHSU - Estados Unidos
Oregon Health & Science University - Estados Unidos |
| 11 | Winters, Carmen | Mujer |
OHSU - Estados Unidos
Oregon Health & Science University - Estados Unidos |
| 12 | Morgan, Terry | Hombre |
OHSU - Estados Unidos
Oregon Health & Science University - Estados Unidos |
| 13 | Perrin, Lewis C. | Hombre |
UNIV QUEENSLAND - Australia
The University of Queensland - Australia |
| 14 | Hooper, John D. | Hombre |
UNIV QUEENSLAND - Australia
The University of Queensland - Australia |
| 15 | SALOMON-GALLO, CARLOS FRANCISCO | Hombre |
UNIV QUEENSLAND - Australia
Universidad de Concepción - Chile Ochsner Clin Fdn - Estados Unidos UQ Centre for Clinical Research - Australia Ochsner Health System - Estados Unidos The University of Queensland - Australia Ochsner Health - Estados Unidos |
| Fuente |
|---|
| Fondo Nacional de Desarrollo Científico y Tecnológico |
| King Saud University |
| Fondo Nacional de Desarrollo Científico, Tecnológico y de Innovación Tecnológica |
| Fondo Nacional de Desarrollo CientÃfico y Tecnológico |
| University of Queensland |
| Fondo Nacional de Desarrollo CientÃfico, Tecnológico y de Innovación Tecnológica |
| Lions Medical Research Foundation |
| Ovarian Cancer Research Foundation |
| Faculty of MedicineM + BS Emerging LeadersMedical Research Grant |
| UQ-Ochsner Seed Fund for Collaborative Research, The University of Queensland |
| King Saud University (K.S.A), Riyadh |
| Faculty of Medicine M + |
| Agradecimiento |
|---|
| C.S. holds a LionsMedical Research Foundation. M.A. is supported by a scholarship from the King Saud University (K.S.A), Riyadh. Funding sources include: Lions Medical Research Foundation, UQ-Ochsner Seed Fund for Collaborative Research, The University of Queensland, Faculty of MedicineM + BS Emerging LeadersMedical Research Grant, Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT 1170809), and Ovarian Cancer Research Foundation. |
| Funding sources: C.S. holds a Lions Medical Research Foundation . M.A. is supported by a scholarship from the King Saud University (K.S.A), Riyadh. Funding sources include: Lions Medical Research Foundation , UQ-Ochsner Seed Fund for Collaborative Research , The University of Queensland, Faculty of Medicine M + BS Emerging Leaders Medical Research Grant , Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT 1170809 ), and Ovarian Cancer Research Foundation . |